that affect these mitochondrial functions. Knowledge learned from understanding SAs may also help elucidate the pathogenesis of clonal diseases with RS due to recurrent genetic alterations found in these diseases (described below).
Clinically, RARS is a low-risk form of MDS characterized by anemia, dysplasia in the erythroid lineage, and the presence of ≥15% RS in bone marrow (BM) erythroid progenitors. Dysplasia should be minimal in non-erythroid lineages and BM myeloblasts should be less than <5%. RARS accounts for 3-15% of all MDS. The form of MDS known as Refractory Cytopenias with Multilineage Dysplasia (RCMD) should be considered in the differential diagnosis of RARS. In contrast to RARS, RCMD-RS shows bicytopenia or pancytopenia, and dysplasia affecting >10% of the cells in multiple lineages. Generally, patients with RCMD have worse outcome than patients with RARS [3] .
RARS-T was previously classified as a provisional entity with overlapping features of MDS and MPN in WHO 2008 [2] . However, recent genetic analysis of this disease entity has uncovered highly frequent mutations in the spliceosomal gene SF3B1, providing support that RARS-T is a distinct entity, and RARS-T was, therefore, named as MDS/ MPN-RS-T and considered as a distinct entity in WHO 2016 [1] . MDS/MPN-RS-T is diagnosed when there is thrombocytosis (≥450 × 10 9 /L) associated with refractory anemia, dyserythropoiesis in the BM with RS accounting for ≥15% of erythroid precursors, and megakaryocytes with features resembling those in essential thrombocytosis (ET) or primary myelofibrosis (PMF).
Genetic profiles of RARS and MDS/MPN-RS-T and their impact on outcome
In 2011, recurrent somatic mutations in genes encoding spliceosome components, including SF3B1, serine and arginine-rich splicing factor 2 (SRSF2), U2 small nuclear RNA auxiliary factor 1 (U2AF1), and zinc finger CCCH-type RNA binding motif and serine/arginine rich 2 (ZRSR2), were first described in patients with MDS [4, 5] . Amongst these, SF3B1 mutations are most common in patients with RARS, accounting for ~80% of cases, whereas mutations of other spliceosome components are relatively rare (SRSF2 5.5%; U2AF1 0% [5] ). Nearly all SF3B1 mutations are located within the Huntingtin, elongation factor 3, protein phosphatase 2A, and the yeast PI3-kinase TOR1 (HEAT) domains of SF3B1 and occur as heterozygous substitutions. A single mutation (SF3B1K700E) accounts for >50% of SF3B1 mutations in MDS, followed by mutations at the residue K666. Clonal analysis based on the variant allele frequency of SF3B1 and other co-existing mutations revealed that mutations in SF3B1 are present in the dominant clone in most cases. Interestingly, the percentage of BM RS is highly correlated with SF3B1 mutant allele burden [4, [6] [7] [8] , which strongly suggests that mutant SF3B1 directly or indirectly contributes to the formation of RS. In fact, SF3B1 mutations have a high positive predictive value for disease phenotype with RS of 97.7%, whereas the absence of these mutations has an equivalent negative prediction value [7] . These data make SF3B1 the first gene to be strongly related to a specific morphology in myeloid disorders.
In contrast to the diagnostic utility of SF3B1 mutations in RS, the prognostic impact of SF3B1 mutations in MDS with RS is controversial. For example, Malcovati et al. studied the influence of SF3B1 mutations on outcome in 293 patients with myeloid neoplasms with 1% or more RS [6] . In this cohort, SF3B1 mutations were detected in 129 of 159 patients (81%) with RARS or RCMD-RS, and multivariate analysis demonstrated that patients with SF3B1 mutations had significantly better overall survival [hazard ratio (HR) 0.37] and lower cumulative incidence of disease progression (HR 0.31). However, SF3B1 mutations in a similar-sized cohort [288 patients with low-risk MDS; MD Anderson lower risk prognostic scoring system (LR-PSS)] did not impact overall survival (OS) or leukemia-free survival (LFS) [9] . In this study, SF3B1 mutations were detected in 78% of patients with BM RS and frequently co-occurred with DNA methyltransferase 3A (DNMT3A) mutations (p < 0.001). Patnaik et al. studied 107 patients with MDS-RS, including 48 with RARS and 43 with RCMD-RS. SF3B1 mutations were identified in 35 RARS (73%) and 16 RCMD-RS (37%), respectively, and the presence of SF3B1 mutations was associated with better OS (p < 0.01) and LFS (p < 0.01) in univariate analysis [10] . However, mutant SF3B1 was not identified as an independent prognostic factor in further analysis in this study.
Mutational profiles of MDS/MPN-RS-T (RARS-T) have also been studied in several large cohorts [11] [12] [13] . According to these studies, commonly mutated genes in MDS/MPN-RS-T include SF3B1 (85-90%), JAK2V617F (33-77%), TET2 (10-25%), DNMT3A (13-15%), and ASXL1 (15-29%) . Approximately 50% of MDS/MPN-RS-T patients have both SF3B1 and JAK2 mutations, providing an intriguing genetic explanation for the hybrid nature of MDS/MPN-RS-T as being between an MDS and an MPN. This unique genetic profile is particularly valuable for diagnosis, as it is sometimes difficult to distinguish MDS/MPN-RS-T from RARS with reactive thrombocytosis based on morphology alone. Although mutations in the calreticulin gene (CALR) have been reported to be mutually exclusive with JAK2 and MPL mutations and are detected in 67-71% of ET and 56-88% of PMF [14, 15] with wild-type (WT) JAK2 or MPL, mutations in CALR (0-3%) and MPL (1-3%) are not common in MDS/MPN-RS-T [14] [15] [16] .
According to a large study performed by Broseus et al. [17] , patients with MDS/MPN-RS-T have a better median OS than RARS (76 versus 63 months) but an inferior OS when compared to patients with ET (117 months). The leukemic transformation rates are similar in MDS/MPN-RS-T (1.8/100 years) and RARS (2.4/100 years) and higher in MDS/MPN-RS-T in comparison to ET (0.7/100 years). In contrast to RARS, SF3B1 mutations do not seem to have any prognostic impact in MDS/MPN-RS-T. On the other hand, presence of anemia (p = 0.02), abnormal karyotype (p = 0.04), SETBP1 mutations (p = 0.04), and ASXL1 mutations (p = 0.08) have recently been identified as independent predictors of inferior survival in multivariate analysis of 82 patients with MDS/MPN-RS-T [13] . Based on these observations, an HR-weighted prognostic model was developed, in which patients receive 2 points for an abnormal karyotype, 1 point for either SETBP1 and/or ASXL1 mutations, and 1 point for hemoglobin level <10 g/dL. Risk stratification categorized patients into three categories: low (0 point), intermediate (1 point), and high (2 or more points), with median OS of 80, 42, and 11 months, respectively [13] .
Pathophysiology of ring sideroblasts
In contrast to the common pathological features of RS, the underlying molecular mechanisms leading to mitochondrial iron accumulation in SAs are greatly heterogeneous. As described above, our understanding of the pathogenesis of SAs has emerged from discovery of the genetic abnormalities underlying various congenital SAs, and these genetic events effect three processes: (i) heme synthesis, (ii) Fe-S cluster biogenesis and protein synthesis, and (iii) mitochondrial respiration (reviewed recently [18, 19] ) ( Table 1) . Amongst these congenital diseases, X-linked sideroblastic anemia (XLSA) is the most common SA, accounting for 40% of cases [20] . The most frequent form of XLSA is caused by defects involving δ-aminolevulinate synthase (5-aminolevulinate synthase 2; ALAS2). ALAS2 is located at Xp11. 21 and encodes the first and rate-controlling enzyme of the heme biosynthesis pathway that mediates the condensation of glycine and succinyl-CoA to form 5-aminolevulic acid (ALA) in erythroid cells [21, 22] . More than 80 distinct ALAS2 mutations have been identified in >120 unrelated probands. Most of ALAS2 mutations are heterozygous missense mutations that lead to loss-offunction via decrease in ALAS2 expression or defects in catalysis, substrate, or cofactor affinity. Following the discovery of ALAS2 mutations, mutations in solute carrier family 25 member 38 (SLC25A38), the second causal gene implicated in SAs, were reported in 2009 [23] . SLC25A38 encodes an erythroid-specific mitochondrial inner membrane carrier protein. More than 30 patients with SLC25A38-mutated XLSA have been reported so far, accounting for ~15% of congenital SAs, and mutations in SLC25A38 include missense as well as nonsense and splicing errors [23, 24] . SLC25A38 is thought to be an amino acid transporter required for importing glycine across the inner mitochondrial membrane in the initial steps of heme synthesis. Although transmembrane protein 14C (TMEM14C) is also involved in the terminal steps of heme synthesis pathway [25] , no mutations in this gene have been reported in congenital SAs so far.
Two subsequently recognized forms of SA, XLSA with ataxia (XLSA/A) and glutaredoxin 5 (GLRX5) deficiencies, are due to mutations in genes involved in the Fe-S pathway, an essential pathway of mitochondrial iron utilization. Fe-S clusters are generated from iron imported into mitochondria and participate in proteins regulating heme synthesis, cellular iron uptake, and iron storage, such as ferrochelatase (FECH; the final enzyme in the heme biosynthesis pathway) and iron regulatory protein 1 (IRP1). XLSA/A has been described in four families so far and is characterized by mild to moderate microcytic SA accompanied by neurologic deficits of delayed motor and cognitive development, impaired coordination, and cerebellar hypoplasia [26, 27] . XLSA/A is caused by missense mutations in ATP-binding cassette sub-family B member (ABCB7) [28] . This gene is located at Xp13.3 and encodes an essential component of the Fe-S cluster machinery, which is postulated to participate in the export of Fe-S clusters generated in mitochondria [29] . It is, therefore, speculated that iron remains trapped in mitochondria and the level of Fe-S cluster-dependent enzyme activity is decreased in ABCB7 mutant cells. In fact, it has been shown that expression of mutant ABCB7 impairs the maturation of cytosolic Fe-S proteins in yeast in which ATM1, a functional orthologue of ABCB7, is deleted, whereas expression of wild-type (WT) ABCB7 fully rescued the defect [28] . Importantly, defects in ABCB7 are predicted to decrease the activity of FECH via impaired binding between these two proteins, thus blocking the heme biosynthesis. In 2007, a patient with microcytic hypochromic SA presenting in midlife was reported to have a homozygous splice site mutation in GLRX5 [30] , which resulted in reduced mRNA and protein levels of GLRX5. GLRX5 is a mitochondrial protein involved in Fe-S cluster biogenesis. Mutations in GLRX5 result in loss of Fe-S cluster in IRP1, which in turn suppresses ALAS2 translation by binding to the iron responsive element positioned at the 5′-untranslated region of ALAS2. In addition, a global defect in mitochondrial protein translation can lead to congenital SAs, although the mechanism for iron accumulation in mitochondria is unclear.
Congenital SAs caused by genetic abnormalities classified into the third category include mitochondrial myopathy, lactic acidosis, and SA (MLASA) and Pearson's marrow-pancreas syndrome (PMPS). MLASA is an autosomal recessive disorder with muscle weakness, normocytic anemia, and lactic acidosis. Gene mutations in pseudouridine synthesis 1 (PUS1) and mitochondrial tyrosyl transfer RNA synthetase 2 (YARS2) result in MLASA [31, 32] . Mutations in these genes are likely to cause defects in decreased mitochondrial protein synthesis and respiratory chain dysfunction. Deletions, rearrangements, or duplications of mitochondrial DNA also induce the rare syndromic disorder with SA, known as PMPS, which is accompanied with metabolic acidosis and endocrine pancreatic insufficiency [33] . Recently, mutations in NADH:ubiquinone oxidoreductase subunit B11 (NDUFB11) [34] , HSPA9 [the mitochondrial heat-shock protein family A (Hsp70) member 9] [35] , and TRNT1 (tRNA nucleotidyl transferase 1) in SIFD (congenital SA associated with B-cell immunodeficiency, periodic fevers, and developmental delay) [36] have been identified to cause SAs in this category as well.
Given that RARS and other clonal myeloid diseases with RS have a similar morphological phenotype as SAs with regard to iron overload in mitochondria, discoveries from congenital SAs may provide us with insights into the pathogenesis of SAs observed in clonal conditions. In fact, gene expression analysis of RARS has identified dysregulated genes involved in iron metabolism and mitochondrial functions relative to refractory cytopenias with unilineage dysplasia (RCUD) and control samples [37] . For example, expression of mitochondrial transporters (SLC25A37 and SLC25A38) and aminolevulinate dehydratase (ALAD), which has a direct role in heme formation, are deregulated in RARS. Moreover, significant differences are observed between patients with SF3B1 mutations and patients without SF3B1 mutations [37] . Further investigations on these deregulated genes in relation to mis-splicing mediated by mutant SF3B1 are reviewed below.
General mechanisms of pre-mRNA splicing and mis-splicing by mutant SF3B1
As noted earlier, SF3B1 mutations, but not mutations in other spliceosomal genes, are clearly correlated with RS in MDS. Given the essential role of SF3B1 in precursor messenger RNA (pre-mRNA) splicing, this observation strongly supports the idea that SF3B1 mutations play fundamental roles in the disease formation of RARS and other myeloid disorders with RS via pre-mRNA missplicing. Pre-mRNA splicing is the processes of removing introns from pre-mRNA, representing a critical step in the post-transcriptional regulation of gene expression. Splicing is carried out in the nucleus by an enzymatic complex known as the spliceosome. The spliceosome consists of 5 small nuclear ribonucleoproteins (snRNPs; U1, U2, U4, U5, and U6 snRNPs), each of which contains its own small nuclear RNA (snRNA), and more than 200 related proteins. Splicing catalysis involves two sequential transesterification reactions that are achieved in a complex multistep process (reviewed in Refs. [38] [39] [40] [41] [42] [43] ), where base pairing of snRNAs to conserved sequences on pre-mRNA as well as interactions of a variety of splicing accessory proteins and RNA-protein interactions are essential in guiding this dynamic process. An intron is defined by four consensus elements: (i) the 5′ splice site (5′ SS; located at the 5′ end of the intron), (ii) the 3′ SS (the 3′ end of the intron where the AG dinucleotide is located at the intronexon junction), (iii) the branch point sequence (BPS) (located upstream of the 3′ SS), and (iv) the polypyrimidine tract (located between the BPS and the 3′ SS) (Fig. 1a) . U1 snRNA, U2AF1, splicing factor 1 (SF1), and U2AF2 bind the sequences noted above to form complex E. This complex augments the recruitment of U2 snRNP to the BPS. SF3B1 is a component of U2 snRNP and is involved in the binding to the BPS. Following binding of U2 snRNP, other complexes join to induce conformational rearrangements and the subsequent two-step esterification reactions to mediate excision of the intron and ligation of the proximal and distal exon to generate mature mRNA (Fig. 1a) .
Pathological significance of SF3B1 mutations in RARS and RARS-T
Since the initial discovery of spliceosomal mutations (reviewed in [44] ), major advances have been made in understanding the biological consequences and molecular mechanisms of spliceosomal mutations. Our understanding of the roles of mutant SF3B1 has been greatly promoted through analysis of the phenotypes of genetically engineered mice and molecular analysis of Fig. 1 Splicing catalysis, the spliceosome assembly pathway, and mechanisms of splice site selection in SF3B1 wild-type (WT) and mutant (MUT) cells. a Diagram of the 2 sequential transesterification reactions that represent the crucial catalytic steps in intron removal during splicing. An adenine nucleotide (termed the "invariant adenine") of the branch point sequence (BPS) initiates the first transesterification and generates a free 5′ exon and an intron-3′ exon lariat. The 3′ end hydroxyl of the free 5′ exon then attacks the intron-3′ exon junction, completing the splice and releasing a lariat RNA intron. a Mechanisms of splice site selection in SF3B1 WT cells. An intron is defined via (i) the 5′ splice site, (ii) the 3′ splice site, (iii) the branch point sequence (BPS), and (iv) the polypyrimidine (Poly-Y) tract. The definition of an intron depends on recognition of the 5′ splice site and BPS by U1 and U2 small nuclear ribonucleoproteins (snRNPs), respectively. The earliest complex (complex E) is established by binding of (i) U1 snRNP to the 5′ splice site, (ii) splicing factor 1 (SF1) to the BPS, (iii) U2AF2 (also known as U2AF65) to the polypyrimidine tract, and (iv) U2AF1 (also known as U2AF35) to the 3′ SS. Formation of complex E in turn enhances the recruitment of U2 snRNP to the BPS and leads to the formation of complex A. SF3B1, a component of U2 snRNP, is involved in the binding to the BPS. Further assembly of other spliceosomal components, conformational rearrangements, and the two-step esterification reactions that mediate excision of the intron and ligation of the proximal and distal exon to synthesize mature mRNA follows these reactions. b Potential mechanisms of splice site selection in SF3B1 mutant cells. Our current understanding suggests that aberrant splicing mediated by mutant SF3B1 utilizes a cryptic AG, and requires the canonical 3′ splice site. Moreover, the cryptic AG requires the downstream canonical polypyrimidine tract to cause alternative splicing, and three adenosines upstream of the cryptic AG are part of the BPS for mutant SF3B1 but not for WT SF3B1 isogeneic cell lines, yeast models, mouse models, and patient samples.
Two recent studies addressed the biological effects of expression of SF3B1K700E in hematopoiesis in vivo through generation of knock-in (KI) mice with Sf3b1K700E expression as well as RNA sequence analysis of both these mice and MDS patient samples [45, 46] Extensive RNA-seq analysis of six SF3B1 mutants and four SF3B1 WT MDS patient samples also showed that the most common aberrant splicing event was usage of alternative 3′ splice site (68%). The location of the cryptic 3′ splice site in mouse and human cells was both between −15 and −24 nucleotides upstream of the canonical 3′ splice site (Fig. 1b) , which is similar to RNA-seq data from lineage − BM cells of Sf3b1 +/K700E mice generated by Mupo et al. [46] , isogenic cell lines [49] , or clinical samples from patients with a variety of cancer types with SF3B1 mutations [49, 50] .
Darman et al. further studied the motif sequences associated with cryptic and canonical AG dinucleotides in SF3B1 mutant cells and found that (i) pyrimidines are enriched upstream of the canonical AG, which is in agreement with the presence of the polypyrimidine tract, (ii) the cryptic AGs are associated with a short and weak polypyrimidine tract, and (iii) adenosines are enriched upstream of the cryptic AG in both mouse and human cells expressing mutant SF3B1 (Fig. 1b) [49] . The finding that adenosines are enriched upstream of the cryptic AG is particularly interesting because these adenosines could play an important role when mutant SF3B1 recognizes a different BPS. To understand the roles of 3′ SS sequences in early assembly of the spliceosome, particularly how the U2AF2/U2AF1 complex recognizes the polypyrimidine tract and AG, they selected the exon 9/exon 10 junction in ZDHHC16 to develop a series of minigenes because this event is robustly mis-spliced by all SF3B1 hotspot mutants. These experiments demonstrated the following insights: (i) the cryptic AG is necessary for SF3B1-mutant aberrant splicing, (ii) the short polypyrimidine tract upstream of the cryptic AG is not recognized by the U2AF complex, (iii) mutant SF3B1 requires the canonical 3′ SS, (iv) the cryptic AG requires the downstream canonical polypyrimidine tract to cause alternative splicing, (v) three adenosines between −33 and −35 nucleotides upstream of canonical AG are part of the BPS for mutant SF3B1 but not for WT SF3B1, and (vi) −30 and −34 adenosines are the BPs used for WT and mutant SF3B1, respectively. These observations provide at least one model to explain the mechanisms of differential splicing caused by WT and mutant SF3B1 (Fig. 1b) .
The regions of SF3B1 affected by mutations in cancer are remarkably conserved amongst species and this has allowed two groups to generate mutations in the yeast orthologue of SF3B1, termed Hsh155 [51, 52] . In both of these studies, MDS disease-associated mutations in SF3B1 altered interaction between SF3B1 and the protein Prp5, which is a helicase responsible for the first ATP-dependent step in splicing. Based on these results, further work is now needed to demonstrate how altered interaction between Hsh155 and Prp5 contribute to aberrant splicing by SF3B1 and highlight the potential for further aberrant protein-protein interactions generated by disease-associated mutations in SF3B1.
While we still do not fully understand how aberrant splicing mediated by mutant SF3B1 relates to the phenotype of RS, it has been shown that mRNA and protein expression levels of ABCB7 are downregulated in B-lymphoid leukemia (Nalm-6) cells expressing SF3B1K700E compared to isogeneic SF3B1 WT Nalm-6 cells due to aberrant splicing of ABCB7 leading to NMD [49] . These results may at least partially explain the association between downregulation of ABCB7 in RARS and the presence of SF3B1 mutations; however, further demonstration of this event with mutations in SF3B1 other than K700E is currently lacking. Moreover, it will be important to evaluate the effect of restoration of ABCB7 aberrant splicing and expression in the setting of continued expression of SF3B1K700E to fully confirm the importance of this single splicing event to RS pathogenesis.
Recurrent missense mutations in SF3B1 are generally considered as change-of-function mutations. The vast majority of SF3B1 mutations identified in MDS or other solid tumors are clustered in HEAT domains, mainly involving a few hot spot amino acid position. Recent structural insights into the SF3B1 structure have elucidated that recurrent mutations in SF3B1 occur at sites critical for contacting the BPS [53] . In addition, two studies of Sf3b1 KO mice demonstrated that haploinsufficiency of Sf3b1 leads to reduction of hematopoietic stem and progenitor cells (HSPCs) and compromised reconstitution capacity in competitive and non-competitive transplantation [54, 55] , similar to the phenotypes of Sf3b1 KI mice [45] . However, RNA-seq analysis of LSK cells from Sf3b1 heterozygous KO mice suggests that heterozygous loss of Sf3b1 does not confer the same changes in splicing as the point mutations in SF3B1 described in RS [54] . In aggregate, these observations indicate that SF3B1 mutations confer a change-of-function.
The other issue to be discussed regarding the phenotype of Sf3b1 KI and KO mice is the impact of the mutant allele upon the formation of RS. There are conflicting reports regarding whether Sf3b1 haploinsufficiency causes RS formation. Visconte et al. described rare sideroblasts in the BM of Sf3b1 +/− mice [56, 57] . In contrast, two other groups quantified the number of RSs in the BM of the same Sf3b1 +/− mice [58] and Sf3b1 +/+ mice and found no differences between these animals [54, 55] . Furthermore, both independent strains of conditional Sf3b1 +/K700E mice [45, 46] did not show any significant increase in RSs in BM or peripheral blood, suggesting that physiologic expression of Sf3b1K700E does not cause RS formation in mice. Considering the strong correlation between SF3B1 mutations and RS formation in humans, it is speculated that this discrepancy is due to minimal overlap in mis-spliced genes and events between human MDS and murine models as shown in these papers [45, 46] and/or unknown differences in mitochondrial iron metabolism between human and mouse erythroid precursors. In fact, although ABCB7 is consistently downregulated in human cells with SF3B1K700E expression due to alternative splicing and subsequent NMD, this is not the case with Sf3b1
mice because of the distinct intronic sequence in ABCB7 between mouse and man. In addition, it has been reported that RSs are not observed in conditional Abcb7 KO mice [59] . These results also raise another possibility that other deregulated genes, alone or in combination with ABCB7 downregulation, are responsible for the formation of RS. To this end, Mupo et al. examined expression of Tmem14c, Alas2, and Slc25a37 (mitochondrial iron importer) as well as Abcb7 in their Sf3b1 K700E/WT KI mice [60] . However, no altered expression of these genes was detected in LSK cells in this model [46] . With regard to SLC25A37 (also known as Mitoferrin-1), RNA-seq of MDS patient samples with or without SF3B1K700E mutations demonstrated an increase in a transcript with retained intron in SF3B1 mutant samples compared to SF3B1 WT controls [61] . Although functional studies for this transcript have not been studied, SLC25A37 is a protein localized in the inner membrane of the mitochondria, which acts as an importer of Fe 2+ into the mitochondria in erythroid precursors, and thereby could be implicated in the pathogenesis of RS.
Therapeutic intervention for SF3B1 mutant malignancies
Compared to the remarkable progress in understanding the roles of WT and mutant SF3B1 in hematopoiesis and splicing, there has been considerably less investigation into whether cancer cells with mutant SF3B1 can be pharmacologically targeted or not. According to evidence-based and consensus-based recommendations, patients with RARS or RCMD-RS with asymptomatic cytopenias and without adverse cytogenetic features do not need treatment [62] . However, aggressive therapies, including the hypomethylating agents azacitidine or decitabine and allogeneic stem cell transplantation should be considered if disease progression is observed (reviewed recently [63] ).
In terms of the relationship between SF3B1 mutations and clinical response, there is an interesting observation from a phase II clinical trial of the compound luspatercept (ACE-536) for MDS patients with low or intermediate-1 International Prognostic Scoring System (IPSS) risk who are not candidates or unresponsive/refractory to erythropoiesis-stimulating agents (ESAs; ongoing study reviewed in [64] ). In this study, 82% of patients achieved an erythroid hematological improvement, with a significantly higher response rate in patients with RSs and SF3B1 mutations, although the number of non-sideroblastic patients was small. Luspatercept is a fusion protein that contains a modified extracellular domain of the human activin receptor type IIB linked to a human IgG1 Fc domain, which is shown to sequester TGF-β superfamily ligands to suppress SMAD2/3 activation [65] . It is currently unknown if the efficacy of this agent in low-risk MDS patients is due to an unrecognized association between SF3B1 mutations and TGF-β signaling or not. Base on the results of this phase II study, several clinical trials of luspatercept are currently ongoing for MDS patients (clinicaltrial.gov identifiers NCT02631070, NCT02268383, NCT01749514) and may clarify this association.
Hypomethylating agents are a well-established treatment option for higher risk MDS and AML and azacitidine has been shown to prolong survival in higher risk MDS patients [66] . Hypomethylating agents may also be an therapeutic option for lower risk non-del(5q) MDS patients who are unresponsive or refractory to ESAs. Intriguingly, the SF3B1 mutation was found to be the only factor associated with a significantly improved erythroid response to azacitidine in a randomized phase II trial of azacitidine with or without epoetin-β for MDS patients in low or intermediate-1 IPSS risk with transfusion dependence who showed resistance to or relapsed after high-dose ESAs [67] . According to this study, the erythroid response was 49% (29/59) in SF3B1 mutant patients versus 22% (6/22) in SF3B1 WT patients (p = 0.02). This result may potentially indicate currently undefined links between mis-splicing and epigenetic dysregulation.
Lenalidomide is another compound approved for treating anemia in lower risk MDS patients with 5q deletion (del(5q)), where it yields transfusion independence in 60-75% of cases and a complete or partial cytogenetic response in 40-60%. However, an analysis of clonal architecture of non-del(5q) MDS patients who were treated with lenalidomide alone or lenalidomide plus epoetin-β showed that lenalidomide is unlikely to eradicate MDS clones bearing SF3B1 mutations [68] . The telomerase inhibitor imetelstat is another class of drug that is suggested to show preferential effects against myelofibrosis patients with SF3B1 or U2AF1 mutations versus patients without these mutations (complete response rate, 38 versus 4%, p = 0.04) [69] . However, testing of imetelstat in forms of MDS where >80% of patients harbor SF3B1 mutations, including patients with RARS and RARS-T, resulted in only modest effects in these patients. For these reasons, results from larger clinical trials of imetelstat in myeloid malignancy patients are clearly needed.
Importantly, several natural products from bacterial species and their analogs have been discovered that bind SF3B1 (and possibly other components of U2 snRNP) and block early spliceosome assembly. These compounds, which include E7107 (an analog of pladienolide B) [70] , spliceostatin A [71] , and the sudemycins [72] , are thought to inhibit the binding of the branch point binding region of U2 snRNP to the BPS and block the essential conformational change in U2 snRNP [73] [74] [75] [76] + chimerism in the peripheral blood at 4 weeks post-transplant, the recipient mice were treated with E7107 or vehicle for a total of 10 days. Amongst these four groups, only the Sf3b1 +/K700E recipients treated with E7107 showed a decrease in the chimerism of CD45.2 + cells in both BM and peripheral blood at the end of treatment, indicating that Sf3b1 mutant cells are sensitive to pharmacological modulation of spliceosome compared with WT cells. Detailed analysis of chimerism in the BM revealed a statistically significant decrease in the chimerism of LK cells and a trend of decrease in that of LSK cells. Although the downstream changes in the transcriptome and protein expression induced by these drugs in SF3B1 mutant cells are unknown, these results highlighted the importance of additional studies for the evaluation of spliceosomal inhibitors in isogeneic murine MDS/AML models and, more importantly, in preclinical settings using patient-derived xenograft (PDX) models with mutant SF3B1 expression.
We recently demonstrated that in vivo treatment with E7107 increases retention of both constitutive and alternative introns as well as cassette exon skipping, consistent with E7107 inhibiting splicing catalysis [76] . Although these effects are observed regardless of spliceosomal mutant genotype, the magnitude of splicing inhibition following E7107 treatment was more severe in myeloid leukemias with Srsf2 mutation compared to Srsf2 WT leukemias. This ultimately was associated with decreased disease burden in isogenic murine leukemia models with or without SRSF2 mutations and AML PDX models. In addition, in non-competitive BM transplantation assays, recipient mice reconstituted with hemizygous Mx1-Cre/Srsf2 P95H/− BM mononuclear cells exhibited rapid lethality and severe BM failure due to loss of HSPCs. Conversely, the loss of HSPCs and BM aplasia were not seen in Srsf2 P95H/+ or Srsf2 +/− mice. These results, as well as the observations from in vivo E7107 treatment against Sf3b1 +/K700E hematopoietic cells, suggest that survival of spliceosomal mutant cells may depend on the activity of the residual WT allele and that cells heterozygous for spliceosomal mutations may therefore have increased sensitivity to spliceosomal inhibition (Fig. 2 ). An orally bioavailable analog of E7107, H3B-8800 has shown promising preclinical results in isogenic SRSF2 and SF3B1-mutant leukemias [77] . These data have led to initiation of a phase I dose-escalation study of H3B-8800 for patients with spliceosomal mutant MDS, AML, and CMML (clinicaltrials.gov identifier NCT02841540).
Future direction
Since the discovery of frequent mutations in genes encoding spliceosomal components in MDS and other malignancies, continuous efforts have provided deep insights into the pathogenetic functions of these spliceosomal mutations. Although promising preclinical results of spliceosomal inhibitors have been reported, it is currently unclear if these compounds are effective for cancers that bear multiple genetic defects. Therefore, it will now be important to understand the effects of spliceosomal gene mutations in the context of other genetic abnormalities commonly co-occurring with them. These include mutations in SF3B1 and inv(3)/t(3;3), which activate the proto-oncogene ecotropic viral integration-1 (EVI1) [78] , as well as commonly co-existing mutations in SRSF2 and IDH2 and U2AF1 and ASXL1 [79] [80] [81] . These studies may reveal novel contributions of splicing mutations to cancer and potentially open a novel path to develop therapeutic strategies for spliceosomal mutant cancers. Several genetically engineered spliceosomal mutant mouse models demonstrate MDS-like phenotypes, which have facilitated drug testing in vivo as described above. However, robust MDS patient-derived xenograft models suitable for preclinical studies remain elusive. Development of such models may be critically important for preclinical studies leading to curative therapies for leukemias with aberrant splicing catalysis. 
